You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter to the Editor
Efficacy of omalizumab in the treatment of nasal polyps
  1. María del Carmen Vennera1,
  2. César Picado1,
  3. Joaquim Mullol2,
  4. Isam Alobid2,
  5. Manuel Bernal-Sprekelsen2
  1. 1Department of Pneumology and Respiratory Allergy, Hospital Clínic, CIBERES, Spain
  2. 2Department of Otorhinolaryngology, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
  1. Correspondence to María del Carmen Vennera, Department of Pneumology and Respiratory Allergy, Hospital Clinic, Villarroel 170, Barcelona 08036, Spain; cvennera{at}clinic.ub.es

https://doi.org/10.1136/thx.2010.152835

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Omalizumab, a humanised monoclonal anti-immunoglobulin E (IgE) antibody, is indicated as adjuvant treatment in refractory allergic severe asthma.1 In both chronic rhinosinusitis (CRS) with nasal polyps (NP) and allergic rhinitis, IgE is increased in mucosal tissue and frequently in serum. The role of omalizumab has been clearly established in allergic asthma and rhinitis, but remains to be elucidated in NP.2 The only evidence for the potential efficacy of omalizumab in NP relies on case reports and small series of patients which suggest that, when NP and asthma coexist, the anti-IgE may have therapeutic value on NP.3 4

    We describe the evolution of NP in 19 patients who were treated with omalizumab for severe asthma and who also had …

    View Full Text

    Footnotes

    • Competing interests MdCV and CP have been speakers at continuing medical education meetings supported by Novartis Farmacéutica. JM has been member of National and International Scientific Advisory Boards for UCB, Uriach SA, Schering Plough, Merck Sharp & Dohme, GlaxoSmithKline, FAES and Hartington Pharmaceuticals; has received grants for research projects from Schering-Plough, Uriach SA, UCB and Merck Sharp & Dohme; and has received fees for lectures from UCB, Uriach SA, Schering-Plough, Merck Sharp & Dohme, GlaxoSmithKline and Hartington Pharmaceuticals. IA and MB-S have no conflicts of interest to be declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.